Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

PURPOSE: Cyclin E (CCNE1) has been proposed as a biomarker of sensitivity to adavosertib, a Wee1 kinase inhibitor, and a mechanism of resistance to HER2-targeted therapy. EXPERIMENTAL DESIGN: Copy number and genomic sequencing data from The Cancer Genome Atlas and MD Anderson Cancer Center databases...

Descripción completa

Detalles Bibliográficos
Autores principales: DiPeri, Timothy P., Evans, Kurt W., Raso, Maria Gabriela, Zhao, Ming, Rizvi, Yasmeen Q., Zheng, Xiaofeng, Wang, Bailiang, Kirby, Bryce P., Kong, Kathleen, Kahle, Michael, Yap, Timothy A., Dumbrava, Ecaterina E., Ajani, Jaffer A., Fu, Siqing, Keyomarsi, Khandan, Meric-Bernstam, Funda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618648/
https://www.ncbi.nlm.nih.gov/pubmed/37279095
http://dx.doi.org/10.1158/1078-0432.CCR-23-0103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618648/
https://www.ncbi.nlm.nih.gov/pubmed/37279095
http://dx.doi.org/10.1158/1078-0432.CCR-23-0103

Ejemplares similares